A

Adocia SA
PAR:ADOC

Watchlist Manager
Adocia SA
PAR:ADOC
Watchlist
Price: 9.74 EUR -1.02% Market Closed
Market Cap: 178m EUR

Net Margin
Adocia SA

-100%
Current
-1 019%
Average
-6.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-100%
=
Net Income
-9.3m
/
Revenue
9.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
FR
Adocia SA
PAR:ADOC
178m EUR
-100%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
364.7B USD
6%
US
Amgen Inc
NASDAQ:AMGN
157.9B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
146.8B USD
22%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
100.1B USD
32%
AU
CSL Ltd
ASX:CSL
131.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.4B USD
31%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.7B USD
-13%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Adocia SA
Glance View

Market Cap
178m EUR
Industry
Biotechnology

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.

ADOC Intrinsic Value
24.92 EUR
Undervaluation 61%
Intrinsic Value
Price
A
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-100%
=
Net Income
-9.3m
/
Revenue
9.3m
What is the Net Margin of Adocia SA?

Based on Adocia SA's most recent financial statements, the company has Net Margin of -100%.

Back to Top